Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...

In a recent study published in the journal Nature Cell Biology, researchers investigated how N-acetyltransferase (NAT)-mediated post-translational modification, acetylhypusination, regulates insulin ...

Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b) Denali and Sanofi intend to accelerate DNL788 for ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how the protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia–reperfusion injury by suppressing RIPK1-mediated ...

Receptor-interacting protein kinase 1 (RIPK1) regulates cell cycle and counteracts necroptosis, and is hence considered a target to watch in necroptosis-related conditions such as cancer or ...

Eli Lilly will partner with Rigel Pharmaceuticals to co-develop and commercialize Rigel’s Phase II-bound R552 for all indications—which they emphasized would include autoimmune and inflammatory ...

A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...

Sironax Ltd. has raised $200 million in a series B financing round to support the development of its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. The latest financing has ...

This new article publication from Acta Pharmaceutica Sinica B, discusses the discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model ...